Joshua Zeidner, MD
UNC Lineberger Comprehensive Cancer Center · University of North Carolina, Chapel Hill
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Joshua Zeidner, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:55 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07605949 · Revumenib, Azacitidine, and VENetoclax in Newly Diagnosed KMT2A-Rearranged AMLUNC Lineberger Comprehensive Cancer Center · not yet recruiting · Leukemia Acute Myeloid · principal investigator
- Ph2NCT05442216 · Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating AgentsJoshua Zeidner · recruiting · Acute Myeloid Leukemia · principal investigator
- Ph1NCT04872478 · Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPALMeryx, Inc. · recruiting · Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:55 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in acute myeloid leukemia.